Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;29(4):255-268.
doi: 10.1177/09727531221108871. Epub 2022 Jul 10.

Neurocognitive Changes in Sickle Cell Disease: A Comprehensive Review

Tarun Sahu  1 , Babita Pande  1 , Meenakshi Sinha  1 , Ramanjan Sinha  1 , Henu Kumar Verma  2
Affiliations
Review

Neurocognitive Changes in Sickle Cell Disease: A Comprehensive Review

Tarun Sahu et al. Ann Neurosci. 2022 Oct.

Abstract

Background: Sickle cell disease (SCD) is a type of hemoglobinopathy characterized by abnormal hemoglobin molecules, which includes numerous acute and chronic complications. Ischemic stroke, silent cerebral infarction, headache, and neurocognitive impairment are the most common neurological complications associated with SCD.

Summary: Acute anemia because of SCD can cause cognitive impairments because of cerebral hypoxia. Cognitive abnormalities in SCD manifest in various aspects such as working memory, verbal learning, executive functions, and attention. These neurocognitive impairments have been associated with poor functional results, such as transitioning from juvenile to adult care, adherence to medications, and unemployment.

Key message: In this review, we focus on neurocognitive aspects of SCD patients based on different imaging techniques, psychological batteries, associated neuromarkers, and interventions for managing of cognitive deficiencies..

Keywords: Cognition; Neurocognition; Neuroimaging; Sickle cell disease.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.. Mechanisms Behind Neurocognitive Decline in SCD.
Figure 2.
Figure 2.. Different Events of Cerebral Injury, Their Investigations, and Interventions in SCD.
See this image and copyright information in PMC

References

    1. Piel FB, Steinberg MH, and Rees DC.. Sickle cell disease. N Engl J Med 2017; 376: 1561–1573. - PubMed
    1. Serjeant GR.Sickle-cell disease. Lancet 1997; 350: 725–730. - PubMed
    1. Rees DC, Williams TN, and Gladwin MT.. Sickle-cell disease. Lancet 2010; 376: 2018–2031. - PubMed
    1. Ware RE, de Montalembert M, Tshilolo L, et al.. Sickle cell disease. Lancet 2017; 390: 311–323. - PubMed
    1. Verma HK, Ratre YK, Bhaskar LVKS, et al.. Erythrocyte microRNAs: A tiny magic bullet with great potential for sickle cell disease therapy. Ann Hematol 2021; 100: 607–614. - PubMed